Antonelli A, Saracino A, Alberti B, Melosi A, Cartei F, Lepri A, Laddaga M, Baschieri L
Istituto di Clinica Medica II, Università degli Studi di Pisa.
Clin Ter. 1992 Jan;140(1):25-31.
The most frequently used medical treatment of Graves' ophthalmopathy is the combination of orbital irradiation and systemic corticosteroid. In this study the effectiveness of "high dose intravenous immunoglobulin" (IVIG) in Graves' ophthalmopathy treatment is explored. 11 patients were treated with orbital radiotherapy combined with systemic corticosteroid (Group 1), while 10 patients were treated with the combination of orbital irradiation and IVIG (Group 2). The therapeutic effect was assessed by an ophthalmopathy index based on the American Thyroid Association, classification of ocular changes of Graves' ophthalmopathy. All signs and symptoms of endocrine ophthalmopathy improved significantly in both groups. The mean ophthalmopathy index decreased from 7.0 +/- 1.3 to 3.4 +/- 1.5 in Group 1, and from 7.0 +/- 1.8 to 3.0 +/- 2.1 in Group 2. Statistical analysis showed no significant difference between Group 1 and 2 mean initial and final ophthalmopathy index, and a significant difference between initial and final ophthalmopathy index both in Group 1 and 2. While side effects were present in Group 1 treated with systemic corticosteroid, no side effect was observed in patients treated with IVIG. These preliminary results suggest that IVIG is safe and effective in the treatment of Graves' ophthalmopathy.
格雷夫斯眼病最常用的医学治疗方法是眼眶照射与全身性皮质类固醇联合使用。在本研究中,探讨了“大剂量静脉注射免疫球蛋白”(IVIG)在格雷夫斯眼病治疗中的有效性。11例患者接受眼眶放疗联合全身性皮质类固醇治疗(第1组),而10例患者接受眼眶照射与IVIG联合治疗(第2组)。根据美国甲状腺协会的格雷夫斯眼病眼部变化分类,通过眼病指数评估治疗效果。两组内分泌性眼病的所有体征和症状均有显著改善。第1组的平均眼病指数从7.0±1.3降至3.4±1.5,第2组从7.0±1.8降至3.0±2.1。统计分析显示,第1组和第2组的初始和最终眼病指数平均值之间无显著差异,且第1组和第2组的初始和最终眼病指数之间均有显著差异。虽然接受全身性皮质类固醇治疗的第1组出现了副作用,但接受IVIG治疗的患者未观察到副作用。这些初步结果表明,IVIG在格雷夫斯眼病治疗中是安全有效的。